CollPlant Biotechnologies Ltd Overview
Pro stress-test →CollPlant Biotechnologies is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. The technology is based on plant-derived production of recombinant human collagen type I (rhCollagen), enabling proprietary bioinks and regenerative products.
Strategic Profile
Pro stress-test →The company offers regenerative dermal and soft tissue fillers, 3D-bioprinted regenerative breast implants, and wound care products including VergenixSTR and VergenixFG. The platform leverages plant-based collagen production, creating a differentiated technology moat in the regenerative medicine space.
Competitive Landscape
Pro stress-test →CollPlant competes in regenerative medicine and aesthetic medicine. Direct competitors include other biotech firms developing tissue engineering, bioprinting, and collagen-based therapeutics. The broader competitive set includes Envisiontec (bioprinting), Organogenesis (regenerative medicine), and traditional aesthetic product manufacturers.
Industry Context
CollPlant Biotechnologies Ltd operates in Regenerative Medicine & Bioprinting.
Key facts
Founded: 2004 · Headquarters: Rehovot, Israel · Employees: N/A · Revenue: N/A · Market cap: $25M